SPX-101 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
A phase two study to test the safety and effectiveness of SPX-101 in people with CF is planned.
This program is sponsored by Spyryx Biosciences and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT).
Contact us about SPX-101 >